Triple High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Pediatric Neuroblastoma
- Author:
Myoung Jin WOO
1
;
Sae Rom CHOI
;
Bum Sik KIM
;
Hyo Sun KIM
;
Sung Chul WON
;
Chuhl Joo LYU
Author Information
1. Department of Pediatrics, College of Medicine, Yonsei University, Seoul, Korea. sungchul.won@gmail.com
- Publication Type:Original Article
- Keywords:
Neuroblastoma;
Autologous;
Stem cell transplantation;
Triple
- MeSH:
Disease-Free Survival;
Humans;
Medical Records;
Neuroblastoma;
Retrospective Studies;
Stem Cell Transplantation;
Stem Cells
- From:Clinical Pediatric Hematology-Oncology
2011;18(2):97-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: High-risk group neuroblastoma (HRNB) is one of the most incurable diseases in pediatric oncology field. This report explores the effectiveness, safety and feasibility of triple high dose chemotherapy followed by autologous stem cell transplantation (HDCT/ASCT) in contrast with single HDCT/ASCT for HRNB.METHODS: From Jan. 2001 to Dec. 2009, 25 patients newly diagnosed as HRNB have been analyzed. This study is a retrospective analysis with the medical records of these 25 HRNB patients.RESULTS: Eleven (44%) and the other fourteen (56%) patients were treated with single HDCT/ASCT and triple HDCT/ASCT, respectively. The 5-year event-free survival (EFS) of the whole group in HRNB is 37.2+/-10.0%. The 5-year EFS of single HDCT/ASCT and triple HDCT/ASCT were 27.3+/-13.4% and 46.8+/-13.8%, respectively (P=0.38). Between two groups, there were no statistically significant differences including clinical features, outcome, transplantation-related toxicities, and short-term/long-term complications.CONCLUSION: Triple HDCT/ASCT group showed similar transplantation-related toxicities and long-term complications when compared to single HDCT/ASCT group. We need more exploration to conclude the triple HDCT/ASCT as an optimal treatment for HRNB patients.
